1214353-79-3

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 5-bromo-6-chloropyridine-2-carboxylate is used as an intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic effects. Methyl 5-broMo-6-chloropyridine-2-carboxylate's reactivity and functional groups facilitate the creation of novel molecular entities for treating a range of medical conditions.
Used in Agrochemical Industry:
In the agrochemical sector, Methyl 5-bromo-6-chloropyridine-2-carboxylate is utilized as a precursor in the production of pesticides and other agrochemicals. Its chemical properties make it suitable for the synthesis of compounds with pesticidal activity, contributing to the development of effective solutions for crop protection and management of pests and diseases in agriculture.
Used in Organic Chemistry Research:
Methyl 5-bromo-6-chloropyridine-2-carboxylate is also employed as a research compound in organic chemistry. Its potential for undergoing various chemical reactions makes it a valuable tool for exploring new synthetic pathways and understanding the reactivity of different functional groups. Methyl 5-broMo-6-chloropyridine-2-carboxylate can contribute to the advancement of organic chemistry and the discovery of new chemical entities with potential applications in various fields.
Safety Precautions:
It is crucial to handle Methyl 5-bromo-6-chloropyridine-2-carboxylate with care due to its potential health hazards and flammability. Proper safety measures, including the use of personal protective equipment and adherence to laboratory safety protocols, should be followed to minimize risks associated with its use.

Upstream product

• 67-56-1 methanol 
• 959741-37-8 5-bromo-2-carboxypyridin-1-ium-1-olate 
• 30766-11-1 5-bromoisonicotinic acid 
• 959741-32-3 5-bromo-2-(methoxycarbonyl)-1^A[5]-pyridin-1-olate 
• 29682-15-3 methyl 5-bromopicolinate 

Downstream Products

• 1415898-28-0 5-cyclopropyl-6-(2,4-dichloro-phenylamino)-pyridine-2-carboxylic acid methyl ester 
• 1415898-29-1 5-cyclopropyl-6-(2,4-dichloro-phenylamino)-pyridine-2-carboxylic acid 
• 1415899-33-0 6-(3-chloro-phenyl)-5-(3,3-difluoro-azetidin-1-yl)-pyridine-2-carboxylic acid 
• 1227563-64-5 (5-bromo-6-chloropyridin-2-yl)methanol 
• 1613298-71-7 benzyl 4-(2-amino-2-oxo-ethyl)-4-[[5-cyclopropyl-6-(cyclopropylmethoxy)pyridine-2-carbonyl]amino]piperidine-1-carboxylate 
• 959958-25-9 5-bromo-6-chloropyridine-2-carboxylic acid 

Relevant academic research and scientific papers

TRIAZOLOPYRIMIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS

The present invention relates to compounds of general formula I, wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.

PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS

There are provided inter alia pyrazolyl-substituted pyridone compounds, which exhibit biological activity, e.g., inhibitory action, against serine proteases, including thrombin and various kallikreins. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which disease or disorder is amenable to treatment or prevention by the inhibition of serine proteases, including thrombin and various kallikreins.

Discovery of a high affinity and selective pyridine analog as a potential positron emission tomography imaging agent for cannabinoid type 2 receptor

As part of our efforts to develop CB2 PET imaging agents, we investigated 2,5,6-substituted pyridines as a novel class of potential CB2 PET ligands. A total of 21 novel compounds were designed, synthesized, and evaluated for their potency and binding properties toward human and rodent CB1 and CB2. The most promising ligand 6a was radiolabeled with carbon-11 to yield 16 ([11C]RSR-056). Specific binding of 16 to CB2-positive spleen tissue of rats and mice was demonstrated by in vitro autogadiography and verified in vivo in PET and biodistribution experiments. Furthermore, 16 was evaluated in a lipopolysaccharid (LPS) induced murine model of neuroinflammation. Brain radioactivity was strikingly higher in the LPS-treated mice than the control mice. Compound 16 is a promising radiotracer for imaging CB2 in rodents. It might serve as a tool for the investigation of CB2 receptor expression levels in healthy tissues and different neuroinflammatory disorders in humans.

NOVEL PYRIDINE DERIVATIVES

The invention relates to a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS

The invention relates to CB2 agonists of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

AROMATIC RING COMPOUND

Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.

AROMATIC RING COMPOUND

Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.

PYRIDIN- 2 -AMIDES USEFUL AS CB2 AGONISTS

The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

NOVEL PYRIDINE DERIVATIVES

The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.